Peter Pushko

Summary

Publications

  1. doi request reprint Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes
    Peter Pushko
    Medigen, Inc, 4539 Metropolitan Court, Frederick, MD, USA
    Vaccine 29:5911-8. 2011
  2. pmc Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens
    Peter Pushko
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA Electronic address
    Virology 501:176-182. 2017
  3. pmc Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model
    Peter Pushko
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA Electronic address
    Vaccine 34:5235-5242. 2016
  4. pmc Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus
    Peter Pushko
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD, USA Electronic address
    Vaccine 33:4975-82. 2015
  5. doi request reprint Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus
    Peter Pushko
    Novavax, Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 28:4771-6. 2010
  6. ncbi request reprint Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza
    Peter Pushko
    Novavax Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 25:4283-90. 2007
  7. pmc Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle
    Rick A Bright
    Novavax, Inc, Rockville, Maryland, USA
    PLoS ONE 3:e1501. 2008
  8. ncbi request reprint Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin
    Rick A Bright
    Novavax, Inc, Rockville, MD 20850, USA
    Vaccine 25:3871-8. 2007
  9. doi request reprint Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses
    Irina Tretyakova
    Medigen, Inc, 4539 Metropolitan Court, Frederick, MD, USA
    Virology 442:67-73. 2013
  10. pmc Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein
    Irina Tretyakova
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD, USA
    Virology 487:163-71. 2016

Collaborators

Detail Information

Publications18

  1. doi request reprint Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes
    Peter Pushko
    Medigen, Inc, 4539 Metropolitan Court, Frederick, MD, USA
    Vaccine 29:5911-8. 2011
    ..We conclude that this technology may represent a novel strategy for rapid development of trivalent seasonal and pandemic vaccines...
  2. pmc Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens
    Peter Pushko
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA Electronic address
    Virology 501:176-182. 2017
    ..Immune response was also detectable after challenge with low pathogenicity AI (LPAI) H9N2 virus suggesting that H5/H7/H9/N1/gag VLPs represent a promising approach for the development of broadly protective AI vaccine...
  3. pmc Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model
    Peter Pushko
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA Electronic address
    Vaccine 34:5235-5242. 2016
    ....
  4. pmc Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus
    Peter Pushko
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD, USA Electronic address
    Vaccine 33:4975-82. 2015
    ..Immunogenicity and protective efficacy of rH7 SVPs was confirmed in the mouse and ferret challenge models suggesting that SVPs can be used for vaccination against H7N9 virus. ..
  5. doi request reprint Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus
    Peter Pushko
    Novavax, Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 28:4771-6. 2010
    ..Moreover, a single 15mug dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus...
  6. ncbi request reprint Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza
    Peter Pushko
    Novavax Inc, 9920 Belward Campus Drive, Rockville, MD 20850, USA
    Vaccine 25:4283-90. 2007
    ..Positive effect of the adjuvant was also detected using the rH9 vaccine. The results have implications for the development of safe and effective vaccines for avian influenza viruses with pandemic potential...
  7. pmc Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle
    Rick A Bright
    Novavax, Inc, Rockville, Maryland, USA
    PLoS ONE 3:e1501. 2008
    ....
  8. ncbi request reprint Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin
    Rick A Bright
    Novavax, Inc, Rockville, MD 20850, USA
    Vaccine 25:3871-8. 2007
    ..Interestingly, VLPs elicited antibodies that recognized a broader panel of antigenically distinct H3N2 viral isolates compared to rHA or WIV in a hemagglutination-inhibition (HAI) assay...
  9. doi request reprint Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses
    Irina Tretyakova
    Medigen, Inc, 4539 Metropolitan Court, Frederick, MD, USA
    Virology 442:67-73. 2013
    ..Intranasal vaccination of ferrets with the VLPs resulted in induction of serum antibody responses and efficient protection against experimental challenges with H5N1, H7N2, and H9N2 viruses...
  10. pmc Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein
    Irina Tretyakova
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD, USA
    Virology 487:163-71. 2016
    ..Electron microscopy showed that Bgag-based VLPs resembled influenza virions with the diameter of 150-200nm. This is the first report of quadri-subtype design for influenza VLP and the use of Bgag for influenza VLP preparation. ..
  11. pmc Next generation sequencing of DNA-launched Chikungunya vaccine virus
    Rachmat Hidajat
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA
    Virology 490:83-90. 2016
    ..064% and 0.086%, while in the 181/25, frequencies were 0.179% and 0.133%, respectively. We conclude that the DNA-launched virus has a reduced probability of reversion mutations, thereby enhancing vaccine safety. ..
  12. pmc DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice
    Irina Tretyakova
    Medigen, Frederick, Maryland
    J Infect Dis 209:1882-90. 2014
    ..Vaccine development against CHIKV has proved challenging. Currently there is no approved vaccine or specific therapy for the disease...
  13. doi request reprint Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets
    Ye V Liu
    Novavax, Inc, 22 Firstfield, Gaithersburg, MD 20878, USA
    Vaccine 33:2152-8. 2015
    ..These results provide support for the development of a safe and effective human VLP vaccine with potent adjuvants against avian influenza H7N9 virus with pandemic potential. ..
  14. ncbi request reprint Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice
    Peter Pushko
    Novavax, Inc, Vaccine Technologies, 1 Taft Court, Rockville, MD 20850, USA
    Vaccine 23:5751-9. 2005
    ..Thus, VLPs represent a potential strategy for the development of human vaccines against avian influenza H9N2 viruses...
  15. pmc Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice
    Irina Tretyakova
    Medigen, Inc, 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA
    Virology 468:28-35. 2014
    ..We conclude that iDNA immunization approach combines characteristics of DNA and attenuated vaccines and represents a promising vaccination strategy for YF...
  16. pmc DNA-launched live-attenuated vaccines for biodefense applications
    Peter Pushko
    a Medigen, Inc, Frederick, MD, USA
    Expert Rev Vaccines 15:1223-34. 2016
    ..With this vaccine technology, the field of DNA vaccines is expanded from those that express subunit antigens to include a novel type of DNA vaccines that launch live-attenuated viruses. ..
  17. pmc Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine
    Irina Tretyakova
    Medigen, Inc, 4539 Metropolitan Court, Frederick, MD 21704, USA
    Vaccine 31:1019-25. 2013
    ..To our knowledge, this is the first example of launching a clinical live-attenuated vaccine from recombinant plasmid DNA in vivo...
  18. doi request reprint Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures
    Peter Pushko
    Medigen Inc, Frederick, MD, USA
    Intervirology 56:141-65. 2013
    ..Further development of safe and efficient VLP nanotechnology may require a rational combination of both approaches...